GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forma Therapeutics Holdings Inc (NAS:FMTX) » Definitions » Total Liabilities

Forma Therapeutics Holdings (Forma Therapeutics Holdings) Total Liabilities : $60.68 Mil (As of Jun. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Forma Therapeutics Holdings Total Liabilities?

Forma Therapeutics Holdings's Total Liabilities for the quarter that ended in Jun. 2022 was $60.68 Mil.

Forma Therapeutics Holdings's quarterly Total Liabilities declined from Dec. 2021 ($62.71 Mil) to Mar. 2022 ($53.30 Mil) but then increased from Mar. 2022 ($53.30 Mil) to Jun. 2022 ($60.68 Mil).

Forma Therapeutics Holdings's annual Total Liabilities declined from Dec. 2019 ($59.84 Mil) to Dec. 2020 ($32.73 Mil) but then increased from Dec. 2020 ($32.73 Mil) to Dec. 2021 ($62.71 Mil).


Forma Therapeutics Holdings Total Liabilities Historical Data

The historical data trend for Forma Therapeutics Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forma Therapeutics Holdings Total Liabilities Chart

Forma Therapeutics Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Total Liabilities
245.66 59.84 32.73 62.71

Forma Therapeutics Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.97 59.39 62.71 53.30 60.68

Forma Therapeutics Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Forma Therapeutics Holdings's Total Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=35.088+(27.617+-3.5527136788005E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=62.71

Total Liabilities=Total Assets (A: Dec. 2021 )-Total Equity (A: Dec. 2021 )
=561.061-498.356
=62.71

Forma Therapeutics Holdings's Total Liabilities for the quarter that ended in Jun. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=33.464+(27.213+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=60.68

Total Liabilities=Total Assets (Q: Jun. 2022 )-Total Equity (Q: Jun. 2022 )
=475.169-414.492
=60.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Forma Therapeutics Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of Forma Therapeutics Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Forma Therapeutics Holdings (Forma Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
300 North Beacon Street, Suite 501, Watertown, MA, USA, 02472
Forma Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. The firm's pipeline products are Etavopivat, FT-7051, FT-8225, and others.
Executives
Agustin Melian officer: EVP, Research & Development C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Brian Andrew Lesser officer: SVP, Commercial Officer C/O FORMA THERAPEUTICS HOLDINGS, INC. 300 NORTH BEACON STREET SUITE 501 WATERTOWN MA 02472
Mary E. Wadlinger officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Jeannette Potts officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Frank D. Lee director, officer: President and CEO C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
David N Cook officer: SVP, Chief Scientific Officer
Patrick F. Kelly officer: SVP, Chief Medical Officer C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Todd Shegog officer: SVP, Chief Financial Officer 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Arturo Md Molina director 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
John E Bishop officer: Chief Technology Officer 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Vickers Selwyn M Md director 600 NORTH 18TH STREET, BIRMINGHAM AL 35203
Thomas G Wiggans director
Frederick Wayne A.i. director 500 W MAIN ST., LOUISVILLE KY 40202
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

Forma Therapeutics Holdings (Forma Therapeutics Holdings) Headlines

From GuruFocus

Forma Therapeutics to Present at the Jefferies Healthcare Conference

By Business Wire Business Wire 06-03-2022

Forma Therapeutics Announces Appointment of New Executive Team Members

By Business Wire Business Wire 06-30-2022